AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the Application:

Claim 1-20 (previously cancelled)

Claim 21 (previously amended): Pharmaceutical composition characterized by comprising a combination of an effective dose of inulin and of an anti-metabolic anti-cancer drug, said combination providing a synergistic anti-cancer effect.

Claim 22 (previously amended): Pharmaceutical composition according to claim 21, wherein the inulin is inulin with a DP up to about 100, or oligofructose or a mixture thereof.

Claim 23 (previously amended): Pharmaceutical composition according to claim 21, wherein the inulin is chicory inulin with a (\overline{DP}) ranging from about 10 to about 30, or oligofructose with a (DP) ranging from 2 to 7 and containing about 5 wt% in total of glucose, fructose and sucrose.

Claim 24 (previously amended): Pharmaceutical composition according to claim 21, wherein the anti-cancer drug is selected from the group consisting of methotrexate, cytarabin, fluorouracil, mercaptopurin, thioguanin, azathioprin and hydroxycarbamide.

Claim 25 (previously added): Pharmaceutical composition according to claim 24 wherein the anti-cancer drug is 5-fluorouracil or methotrexate.

Claim 26 (previously amended): Pharmaceutical composition according to claim 21, which additionally to the said anti-metabolic anti-cancer drug contains one or more anti-cancer drugs belonging to the class of anti-metabolic anti-cancer drugs and/or to another class of anti-cancer drugs.



HAYES SOLOWAY P.C.

130 W. CUSHING ST. TUCSON, AZ 85701 TEL. 520.882.7623 FAX. 520.882.7643

Serial No. 09/700,573 Docket No. Tiense Raff.28 Amendment C with RCE

Claim 27 (previously amended): Pharmaceutical composition according to claim 21, in which the inulin and the anti-metabolic anti-cancer drug which constitute the combination are present in the same galenic formulation.

Claim 28 (previously amended): Pharmaceutical composition according to claim 21, in which the inulin and the anti-metabolic anti-cancer drug which constitute the combination are present in separate galenic formulations which in combination together form the pharmaceutical composition.

Claim 29 (currently amended): Pharmaceutical composition according to claim 21, wherein the single galenic formulation or the separate galenic formulations forming the pharmaceutical composition are which is suitable for oral, parenteral or rectal administration, or for tube feeding.

Claim 30 (previously added): Pharmaceutical composition according to claim 28 in which the inulin is present in a functional food or feed.

Claim 31 (previously added): Pharmaceutical composition according to claim 28 in which the anti-cancer drug is present in a formulation which is suitable for oral or parenteral administration.

Claim 32 (previously amended): Pharmaceutical composition according to claim 21 for use as a medicament for the treatment of cancer in human.

Claim 33 (previously amended): Pharmaceutical composition according to claim 21 for use as a medicament for the treatment of cancer in non-ruminating mammals.

Claim 34 (previously cancelled)

l'art

HAYES SOLOWAY P.C.

130 W. CUSHING ST. TUCSON, AZ 85701 TEL. 520.882.7623 FAX. 520.882.7643

Serial No. 09/700,573 Docket No. Tiense Raff.28 Amendment C with RCE

Claim 35 (previously amended): Method for the treatment of cancer in a human or in a non-ruminating mammal comprising administering to said being in need of such treatment an effective amount of a pharmaceutical composition as defined in claim 21.

Claim 36 (previously added): Method according to claim 35 wherein the inulin and the anti-metabolic anti-cancer drug of the combination forming the pharmaceutical composition are present in the same galenic formulation constituting the pharmaceutical composition.

Claim 37 (previously added): Method according to claim 35 wherein the inulin and the anti-metabolic anti-cancer drug of the combination forming the pharmaceutical composition are present in separate galenic formulations constituting together the pharmaceutical composition.

Claim 38 (previously added): Method according to claim 37 wherein the separate galenic formulations are administered simultaneously or non-simultaneously.

Claim 39 (previously added): Method according to claim 37 wherein the separate galenic formulations are administered via different methods of administration and the inulin is administered by a method selected from the group consisting of oral, parenteral or rectal administration and administration via tube feeding.

Claim 40 (previously added): Method according to claim 39 wherein the separate galenic formulation containing the inulin is a functional food or feed.

Claim 41 (new): Pharmaceutical composition according to claim 28, wherein the separate galenic formulations which in combination form the pharmaceutical composition are suitable for oral, parenteral or rectal administration, or for tube feeding.

l'est.

HAYES SOLOWAY P.C.

130 W. CUSHING ST. TUCSON, AZ 85701 TEL. 520.882.7623 FAX. 520.882.7643

Serial No. 09/700,573 Docket No. Tiense Raff.28 Amendment C with RCE

L'ent

Claim 42 (new): Pharmaceutical composition according to claim 41, wherein the separate galenic formulations are suitable for administration in a different manner from each other.

HAYES SOLOWAY P.C.

130 W. CUSHING ST. TUCSON, AZ 85701 TEL. 520.882.7623 FAX. 520.882.7643